ArsenalBio Secures $325M with Regeneron, BMS Backing
ArsenalBio raises $325M to advance solid tumor CAR-T therapies. Focus on kidney, prostate cancer with innovative genomic technology.
- Latest
- Trending
ArsenalBio raises $325M to advance solid tumor CAR-T therapies. Focus on kidney, prostate cancer with innovative genomic technology.
Exscientia merges into Recursion to form a $850 million AI drug discovery powerhouse, focusing on oncology and rare diseases.
Pharma giant Bristol Myers Squibb acquires RayzeBio for $4.1 billion, expanding its presence in the oncology sector and strengthening its ...
Pharmaceutical giants Bristol Myers Squibb and Johnson & Johnson invest in Accent Therapeutics, a leading RNA drug developer, contributing to ...
Licensing deals and ADCs drive biopharma deal flow in 2023, offering hope to an industry grappling with challenges. Big Pharma's ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.